Vesper Bio doses first volunteer in Phase I study of first-in-class oral treatment for Frontotemporal Dementia

COPENHAGEN, Denmark, Dec. 7, 2023. Vesper Bio ApS ( " Vesper " or " the Company " ), a clinical stage biotech and world leader in sortilin receptor biology, today announces that the first volunteer has been dosed with its lead compound VES001, a patient...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials